Singapore markets open in 1 hour 53 minutes

Cyclerion Therapeutics, Inc. (CYCN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.0000-0.0500 (-1.64%)
At close: 02:54PM EST
3.0000 0.00 (0.00%)
After hours: 05:20PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 7.60M
Enterprise value -1.50M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)55.50
Price/book (mrq)0.59
Enterprise value/revenue -655.82
Enterprise value/EBITDA 0.04

Trading information

Stock price history

Beta (5Y monthly) 1.78
52-week change 3-75.89%
S&P500 52-week change 327.34%
52-week high 313.7200
52-week low 31.7500
50-day moving average 33.3958
200-day moving average 33.4632

Share statistics

Avg vol (3-month) 37.62k
Avg vol (10-day) 33.47k
Shares outstanding 52.45M
Implied shares outstanding 62.45M
Float 81.04M
% held by insiders 122.20%
% held by institutions 145.82%
Shares short (15 Feb 2024) 426.84k
Short ratio (15 Feb 2024) 411.83
Short % of float (15 Feb 2024) 41.56%
Short % of shares outstanding (15 Feb 2024) 41.10%
Shares short (prior month 12 Jan 2024) 425.93k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:20
Last split date 316 May 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)30 Sept 2023


Profit margin 0.00%
Operating margin (ttm)-2,871.91%

Management effectiveness

Return on assets (ttm)-118.39%
Return on equity (ttm)-279.31%

Income statement

Revenue (ttm)1.33M
Revenue per share (ttm)0.59
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -38.09M
Net income avi to common (ttm)-41.05M
Diluted EPS (ttm)-18.5300
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)9.11M
Total cash per share (mrq)3.72
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)4.21
Book value per share (mrq)5.26

Cash flow statement

Operating cash flow (ttm)-26.75M
Levered free cash flow (ttm)-27.44M